NO333440B1 - Syrenoytraliserende og laksativ tablett - Google Patents
Syrenoytraliserende og laksativ tablett Download PDFInfo
- Publication number
- NO333440B1 NO333440B1 NO20031873A NO20031873A NO333440B1 NO 333440 B1 NO333440 B1 NO 333440B1 NO 20031873 A NO20031873 A NO 20031873A NO 20031873 A NO20031873 A NO 20031873A NO 333440 B1 NO333440 B1 NO 333440B1
- Authority
- NO
- Norway
- Prior art keywords
- tablet
- magnesium oxide
- oxide particles
- weight
- antacid
- Prior art date
Links
- 230000002475 laxative effect Effects 0.000 title claims abstract description 24
- 239000008141 laxative Substances 0.000 title claims abstract description 21
- 239000002253 acid Substances 0.000 title claims 2
- 230000003472 neutralizing effect Effects 0.000 title claims 2
- 239000002245 particle Substances 0.000 claims abstract description 95
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 75
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 75
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 75
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 18
- 229940069428 antacid Drugs 0.000 claims abstract description 18
- 239000003159 antacid agent Substances 0.000 claims abstract description 18
- 230000001458 anti-acid effect Effects 0.000 claims abstract description 18
- 239000011163 secondary particle Substances 0.000 claims abstract description 18
- 238000000790 scattering method Methods 0.000 claims abstract description 9
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 15
- 239000011361 granulated particle Substances 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 6
- 229950008138 carmellose Drugs 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
- 239000000347 magnesium hydroxide Substances 0.000 claims description 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
- 238000007908 dry granulation Methods 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 105
- 239000008187 granular material Substances 0.000 description 24
- 239000000523 sample Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 238000004049 embossing Methods 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001219797 Stenia Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001256421 | 2001-08-27 | ||
| PCT/JP2002/006909 WO2003018034A1 (fr) | 2001-08-27 | 2002-07-08 | Comprimes antiacides et laxatifs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031873L NO20031873L (no) | 2003-04-25 |
| NO20031873D0 NO20031873D0 (no) | 2003-04-25 |
| NO333440B1 true NO333440B1 (no) | 2013-06-03 |
Family
ID=19084237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031873A NO333440B1 (no) | 2001-08-27 | 2003-04-25 | Syrenoytraliserende og laksativ tablett |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7147868B2 (fr) |
| EP (1) | EP1421944B1 (fr) |
| KR (3) | KR20080099353A (fr) |
| CN (1) | CN1262278C (fr) |
| AT (1) | ATE380546T1 (fr) |
| AU (1) | AU2002318630B2 (fr) |
| CA (1) | CA2424554C (fr) |
| DE (1) | DE60224056T2 (fr) |
| DK (1) | DK1421944T3 (fr) |
| ES (1) | ES2296960T3 (fr) |
| HK (1) | HK1061641A1 (fr) |
| MX (1) | MXPA03003292A (fr) |
| MY (1) | MY134676A (fr) |
| NO (1) | NO333440B1 (fr) |
| PT (1) | PT1421944E (fr) |
| RU (1) | RU2284189C2 (fr) |
| TW (1) | TWI331044B (fr) |
| WO (1) | WO2003018034A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| US20060165759A1 (en) * | 2005-01-27 | 2006-07-27 | Warner-Lambert Company Llc | Antacid lozenge containing micronized particles |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| GB0714670D0 (en) * | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| GB0720220D0 (en) * | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| KR20100075492A (ko) * | 2007-10-29 | 2010-07-02 | 교와 가가꾸고교 가부시키가이샤 | 완하제 |
| CN102333535A (zh) * | 2009-02-25 | 2012-01-25 | 协和化学工业株式会社 | 氧化镁微粒 |
| RU2517130C2 (ru) * | 2009-04-22 | 2014-05-27 | Киова Кемикал Индастри Ко., Лтд. | Таблетка и пуансон для нее |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| AU2010293637B2 (en) * | 2009-09-08 | 2015-12-03 | Kyowa Chemical Industry Co., Ltd. | Antacid and laxative tablet |
| GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
| CN102283861A (zh) * | 2010-06-17 | 2011-12-21 | 杭州赛利药物研究所有限公司 | 氢氧化镁在制药中的用途以及氢氧化镁制剂和制备方法 |
| PL395069A1 (pl) * | 2011-05-31 | 2012-12-03 | Warszawski Uniwersytet Medyczny | Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego |
| JP2014224080A (ja) * | 2013-05-17 | 2014-12-04 | 協和化学工業株式会社 | 大腸の検査または手術のための処置剤 |
| JP6343338B2 (ja) | 2014-02-25 | 2018-06-13 | 神島化学工業株式会社 | 医薬用又は食品添加用酸化マグネシウム顆粒 |
| CN108686222B (zh) * | 2018-06-13 | 2021-03-19 | 合肥合源药业有限公司 | 瑞舒伐他汀钙组合物的制备方法 |
| TWI724629B (zh) * | 2018-11-16 | 2021-04-11 | 日商協和化學工業股份有限公司 | 緩瀉用錠劑 |
| CN111281855B (zh) * | 2020-03-23 | 2021-09-24 | 乐普制药科技有限公司 | 一种雷贝拉唑肠溶片及其制备方法 |
| CN115487160A (zh) * | 2022-09-27 | 2022-12-20 | 威海百合生物技术股份有限公司 | 一种氧化镁片及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2201594B (en) | 1986-06-24 | 1991-02-13 | Istvan Racz | Production of acid binding pharmaceutical preparations |
| JP2731854B2 (ja) * | 1989-02-10 | 1998-03-25 | 協和化学工業株式会社 | 高耐水和性、高流動性酸化マグネシウムの製造方法 |
| DE3937455A1 (de) * | 1989-11-10 | 1991-05-16 | Nordmark Arzneimittel Gmbh | Antacidatabletten |
| IT1250701B (it) | 1991-07-24 | 1995-04-21 | Angelini Francesco Ist Ricerca | Composizione farmaceutica solida per uso orale a base di dapiprazolo |
| JP2711614B2 (ja) * | 1992-06-10 | 1998-02-10 | 新日本製鐵株式会社 | 皮膜特性及び磁気特性の優れた方向性電磁鋼板の製造方法 |
| JPH0940561A (ja) * | 1995-08-02 | 1997-02-10 | Fujitsukusu Kk | 瀉下剤 |
| JPH10120416A (ja) * | 1996-10-17 | 1998-05-12 | Kyowa Chem Ind Co Ltd | 水懸濁用水酸化マグネシウム粉末 |
| JP2000001428A (ja) * | 1998-04-16 | 2000-01-07 | Nippon Shinyaku Co Ltd | 錠剤及び製造法 |
| JP2001048792A (ja) * | 1998-11-26 | 2001-02-20 | Fujix Kk | 瀉下剤 |
-
2002
- 2002-07-08 KR KR1020087025839A patent/KR20080099353A/ko not_active Application Discontinuation
- 2002-07-08 DK DK02745874T patent/DK1421944T3/da active
- 2002-07-08 KR KR1020037003649A patent/KR100972773B1/ko not_active IP Right Cessation
- 2002-07-08 PT PT02745874T patent/PT1421944E/pt unknown
- 2002-07-08 EP EP02745874A patent/EP1421944B1/fr not_active Expired - Lifetime
- 2002-07-08 CA CA002424554A patent/CA2424554C/fr not_active Expired - Fee Related
- 2002-07-08 AU AU2002318630A patent/AU2002318630B2/en not_active Ceased
- 2002-07-08 US US10/380,407 patent/US7147868B2/en not_active Expired - Fee Related
- 2002-07-08 WO PCT/JP2002/006909 patent/WO2003018034A1/fr active IP Right Grant
- 2002-07-08 DE DE60224056T patent/DE60224056T2/de not_active Expired - Lifetime
- 2002-07-08 CN CNB028027949A patent/CN1262278C/zh not_active Expired - Fee Related
- 2002-07-08 KR KR1020097009958A patent/KR20090065552A/ko not_active Application Discontinuation
- 2002-07-08 AT AT02745874T patent/ATE380546T1/de active
- 2002-07-08 ES ES02745874T patent/ES2296960T3/es not_active Expired - Lifetime
- 2002-07-08 MX MXPA03003292A patent/MXPA03003292A/es active IP Right Grant
- 2002-07-08 RU RU2003112224/15A patent/RU2284189C2/ru not_active IP Right Cessation
- 2002-07-16 TW TW091115825A patent/TWI331044B/zh not_active IP Right Cessation
- 2002-08-26 MY MYPI20023153A patent/MY134676A/en unknown
-
2003
- 2003-04-25 NO NO20031873A patent/NO333440B1/no not_active IP Right Cessation
-
2004
- 2004-06-24 HK HK04104531A patent/HK1061641A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2284189C2 (ru) | 2006-09-27 |
| CN1473049A (zh) | 2004-02-04 |
| MXPA03003292A (es) | 2004-12-13 |
| DK1421944T3 (da) | 2008-03-31 |
| DE60224056T2 (de) | 2008-12-04 |
| EP1421944B1 (fr) | 2007-12-12 |
| ES2296960T3 (es) | 2008-05-01 |
| KR20090065552A (ko) | 2009-06-22 |
| CA2424554C (fr) | 2009-08-18 |
| US7147868B2 (en) | 2006-12-12 |
| PT1421944E (pt) | 2008-01-03 |
| NO20031873L (no) | 2003-04-25 |
| ATE380546T1 (de) | 2007-12-15 |
| US20040022872A1 (en) | 2004-02-05 |
| MY134676A (en) | 2007-12-31 |
| EP1421944A1 (fr) | 2004-05-26 |
| CA2424554A1 (fr) | 2003-03-06 |
| KR20080099353A (ko) | 2008-11-12 |
| KR100972773B1 (ko) | 2010-07-30 |
| AU2002318630B2 (en) | 2007-05-17 |
| DE60224056D1 (de) | 2008-01-24 |
| HK1061641A1 (en) | 2004-09-30 |
| CN1262278C (zh) | 2006-07-05 |
| TWI331044B (en) | 2010-10-01 |
| WO2003018034A1 (fr) | 2003-03-06 |
| NO20031873D0 (no) | 2003-04-25 |
| EP1421944A4 (fr) | 2005-08-31 |
| KR20040044385A (ko) | 2004-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333440B1 (no) | Syrenoytraliserende og laksativ tablett | |
| ES2686081T3 (es) | Dextrosa comprimible directamente | |
| Vodáčková et al. | Evaluation and comparison of three types of spray dried coprocessed excipient Avicel® for direct compression | |
| RU2187999C2 (ru) | Прессуемый лактит и способ его получения | |
| EP2476423A1 (fr) | Comprimé antiacide et laxatif | |
| JP4015485B2 (ja) | 制酸・緩下用錠剤 | |
| Saniocki | New insights into tablet sticking: characterization and quantification of sticking to punch surfaces during tablet manufacture by direct compaction | |
| Okhamafe et al. | Direct Compression Studies on Low-Cost Cellulose derived from Maize Cob. | |
| JP5160156B2 (ja) | 栄養機能食品錠剤 | |
| KR101429331B1 (ko) | 이부프로펜 나트륨 정제 및 이부프로펜 나트륨을 포함하는 제약 조성물의 제조 방법 | |
| Jagtap et al. | Development of directly compressible ascorbic acid tablet using novel excipients | |
| Schiano | Dry Granulation Using Roll Compaction Process: Powder Characterization and Process Understanding | |
| Akpabio et al. | Investigating Corchorus olitorius hydrocolloid as a novel matrix former in sustained release delivery of ibuprofen tablet | |
| US11697632B2 (en) | Storage stable choline chloride compositions | |
| Atanaskova et al. | Investigation of influence on critical process parameters in roller compaction process on physical properties of granules and tablets using design of experiments | |
| JPS59176217A (ja) | 固形薬剤用粉粒体組成物 | |
| Esnaashari Esfahani | The effect of addition of a dry binder on compaction properties of dry granulated particles | |
| CN106535916B (zh) | 片剂型速释性制剂、片剂用组合物及片剂型速释性制剂的制造方法 | |
| Tomar et al. | FORMULATION AND IN VITRO EVALUATION OF METFORMIN HYDROCHLORIDE DIRECT COMPRESSIBLE TABLET USING BY HICEL TM MICROCRYSTALLINE CELLULOSE EXCIPIENT | |
| López Torres | Development of a Generic Pharmaceutical Solid Dosage Form Using Quality by Design (QbD) | |
| Van der Merwe | Effect of powder particle and punch type on the physical and compaction properties of tablets | |
| JP2010248157A (ja) | 魚鱗粉末高濃度含有錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |